These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38678009)

  • 1. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
    Burger PM; Bhatt DL; Dorresteijn JAN; Koudstaal S; Mosterd A; Martens FMAC; Steg PG; Visseren FLJ;
    Eur Heart J Cardiovasc Pharmacother; 2024 Oct; 10(6):488-499. PubMed ID: 38678009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
    Majithia A; Bhatt DL; Friedman AN; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Budoff M; Preston Mason R; Tardif JC; Boden WE; Ballantyne CM
    Circulation; 2021 Nov; 144(22):1750-1759. PubMed ID: 34706555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
    Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
    Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?
    Orringer CE
    Trends Cardiovasc Med; 2020 Apr; 30(3):151-157. PubMed ID: 31101399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.
    Selvaraj S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Juliano RA; Jiao L; Tardif JC; Ballantyne CM;
    J Am Heart Assoc; 2022 Apr; 11(7):e024999. PubMed ID: 35377160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    J Am Heart Assoc; 2022 Mar; 11(6):e022937. PubMed ID: 35261279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
    Verma S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Dhingra NK; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Mason RP; Tardif JC; Ballantyne CM;
    Circulation; 2021 Dec; 144(23):1845-1855. PubMed ID: 34710343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
    Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    Circulation; 2021 Jan; 143(1):33-44. PubMed ID: 33148016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
    Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Med; 2021 Jul; 134(7):e415-e419. PubMed ID: 33450273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it.
    Lan NSR; Fegan PG; Yeap BB; Rankin JM; Watts GF
    Diabetes Obes Metab; 2019 Jul; 21(7):1734-1736. PubMed ID: 30834678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry.
    Picard F; Bhatt DL; Ducrocq G; Ohman EM; Goto S; Eagle KA; Wilson PWF; Smith SC; Elbez Y; Steg PG
    Int J Cardiol; 2021 Oct; 340():96-104. PubMed ID: 34450192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking.
    Miller M; Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Ballantyne CM; Budoff M; Mason RP
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):129-137. PubMed ID: 35953437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.